drugset / Trial / NCT02554877
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM
Timeline
- Start
- 2015-10
- Primary completion
- 2016-08
- Completion
- 2016-08
Outcome
Met primary endpoint
registry Placebo vs PF-06291874 30 mg; p <0.0001; LS Mean difference from placebo -0.91 (95% CI -1.34 to -0.48) NCT02554877 ↗
registry Placebo vs PF-06291874 60 mg; p <0.0001; LS Mean difference from placebo -1.16 (95% CI -1.59 to -0.73) NCT02554877 ↗
registry Placebo vs PF-06291874 100 mg; p <0.0001; LS Mean difference from placebo -1.17 (95% CI -1.60 to -0.74) NCT02554877 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06291874 | Small molecule | 30 mg | Oral |
| Subject | PF-06291874 | Small molecule | 60 mg | Oral |
| Subject | PF-06291874 | Small molecule | 100 mg | Oral |